Status:
RECRUITING
Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide
Lead Sponsor:
Samsung Medical Center
Conditions:
Haploidentical Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
Brief Summary
Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantatio...
Detailed Description
Hematopoietic stem cell transplantation from a haploidentical donor (haplo-HCT) are increasingly used in patients lacking a matched donor, but the optimal strategy needs to be defined. This study aims...
Eligibility Criteria
Inclusion
- Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.
Exclusion
- A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.
Key Trial Info
Start Date :
May 29 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06041893
Start Date
May 29 2023
End Date
December 31 2025
Last Update
December 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea